Company Filing History:
Years Active: 2007-2011
Title: Mamoru Harada: Innovator in Cancer Immunotherapy
Introduction
Mamoru Harada is a distinguished inventor based in Fukuoka, Japan. He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative peptide-based treatments. With a total of 3 patents, Harada's work focuses on harnessing the immune system to combat various forms of cancer.
Latest Patents
One of Harada's latest patents is the "Squamous cell carcinoma antigen-derived peptide binding to HLA-A24 molecule." This invention provides a peptide capable of binding to the HLA-A24 molecule, which is recognized by the cellular immune system. The pharmaceutical composition derived from this peptide is intended for the treatment or prevention of squamous cell carcinoma. Another notable patent is the "HLA-A24-binding KIF-derived peptide." This invention aims to provide a peptide derived from a glioma-associated antigen, which is useful for specific immunotherapy in glioma patients. The KIF-derived peptide also binds to the HLA-A24 molecule and is recognized by the immune system, offering potential therapeutic benefits.
Career Highlights
Throughout his career, Mamoru Harada has worked with reputable institutions such as Kurume University and Green Peptide Co., Ltd. His research and innovations have positioned him as a key figure in the development of peptide-based therapies for cancer treatment.
Collaborations
Harada has collaborated with notable colleagues, including Kyogo Itoh and Ryuya Yamanaka. These partnerships have further enhanced his research and contributed to the advancement of cancer immunotherapy.
Conclusion
Mamoru Harada's innovative work in cancer immunotherapy exemplifies the potential of peptide-based treatments in modern medicine. His contributions continue to pave the way for new therapeutic options for patients battling cancer.